|Day Low/High||82.03 / 83.32|
|52 Wk Low/High||65.44 / 88.76|
Jim Cramer explains the unexpected: quarterly results are 'not as bad as feared' -- NABAF. It's boosting stocks that, based on the headlines, should really just crumple.
Stocks finish down as investors divide their attention between strong third-quarter earnings and concerns over weak U.S. retail sales and the ongoing U.S.-China trade war.
We believe buyers are coming in following the conclusion of the largely positive earnings call.
Abbott Laboratories posted third quarter earnings that were largely in-line with Wall Street forecasts Wednesday, but narrowed its full-year profit forecast.
We are buying this early dip on mixed headline numbers.
Global stocks traded mixed Wednesday, with modest gains in Asia offset by weaker U.S. equity futures, as investors eyed the final hours of Brexit negotiations between Britain and the EU while awaiting around round of third quarter earnings reports on Wall Street.
The Fed is doing this right. Let me repeat... the Fed is not screwing this up.
- Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent
U.S. stock futures decline as Wall Street awaits another round of third-quarter earnings reports and global stocks trade mixed as investors monitored Brexit developments; Netflix, IBM and Bank of America report earnings Wednesday; McKesson, AmerisourceBergen and Cardinal Health reportedly are in talks to pay $18 billion to settle thousands of opioid-related lawsuits.
Kinder Morgan revenue expected to fall 1.3% to $3.5 billion.
Crown Castle International revenue expected to rise 7.5% to $1.5 billion.
U.S. Bancorp revenue expected to rise 2.2% to $5.8 billion.
Progressive revenue expected to rise 11.3% to $9.6 billion.
Tandem will include Abbott's Libre sensor in its insulin pump.
PNC Financial Services Group revenue expected to rise 1.3% to $4.4 billion.
United Rentals revenue expected to rise 15.8% to $2.5 billion.
Jeff fills in for Jim and discusses this morning's earnings from Goldman Sachs, Citigroup, JP Morgan, UnitedHealth Group, and much more!
Abbott Laboratories rises after the medical device company says its board had authorized an additional $3 billion in share repurchases.
- Companies aim to integrate Abbott's FreeStyle Libre glucose sensing technology with Tandem's insulin delivery products to expand choices for people with diabetes
Jeff fills in for Jim and discusses this week's earnings of Goldman Sachs, UnitedHealth Group , Abbott Laboratories, and many more!
- Collaboration combines Abbott′s world-leading glucose sensing technology with Omada Health's best-in-class, proprietary digital coaching platform to provide personalized, on-the-go care
We exited one position, initiated another and upgraded several names last week.
A volatile week ends with heightened expectations for at least one more rate cut from the Fed.
Jim Cramer says earnings worries are weighing on stocks, but investors should seek out companies whose reports are not as bad as everyone feared they would be.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.